Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sonnet Biotherapeutics Holdings Inc (NQ: SONN )

0.8799 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Jul 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.8799
Bid (Size) 0.8546 (1)
Ask (Size) 0.9398 (4)
Prev. Close 0.8799
Today's Range 0.8799 - 0.8799
52wk Range 0.8500 - 10.56
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
-50.01%
-50.01%
1 Month
-55.34%
-55.34%
3 Month
-55.11%
-55.11%
6 Month
-39.94%
-39.94%
1 Year
-91.31%
-91.31%

More News

Read More
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Gold Rises 1%; Accenture Shares Surge After Q3 Results
Via Benzinga
Dow Edges Lower; US Current Account Deficit Widens In Q1
Via Benzinga
Topics Stocks
Exposures US Equities
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
From Sonnet BioTherapeutics Holdings, Inc.
Via GlobeNewswire
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
From Sonnet BioTherapeutics Holdings, Inc.
Via GlobeNewswire
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
From Sonnet BioTherapeutics Holdings, Inc.
Via GlobeNewswire
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
Via ACCESSWIRE
SONN Stock Earnings: Sonnet BioTherapeutics Misses EPS for Q2 2024
Via InvestorPlace
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
Via ACCESSWIRE
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective
Via ACCESSWIRE
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
Via ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
What's Happening With Sonnet BioTherapeutics (SONN) Shares?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.